Biotechnology 13 February 2026 - 19 March 2026

CSL Ltd repurchased 74,167 shares for A$10.3 million on March 18, but shares closed down 2.23% at A$138.00 after warning of a temporary global shortage of its hemophilia B gene therapy HEMGENIX. The stock is now 49% below its 12-month high, following an 81% profit drop, major impairments, and the CEO’s abrupt exit last month.

10x Genomics shares fell 3.3% to $21.40 in premarket trading Friday after CEO Serge Saxonov and CFO Adam Taich disclosed stock sales tied to vested restricted units. The drop follows a 12.6% surge in the prior session. Investors are awaiting a March 3 management appearance for updates on demand.

Beam Therapeutics rose 0.7% to $32.50 premarket Wednesday after a 14% jump Tuesday, following news of a $500 million loan facility with Sixth Street and a longer cash runway into mid-2029. The company flagged a new PKU program and upcoming clinical updates for its liver pipeline. Investors await Phase 1/2 BEAM-302 data by the end of Q1.

Vir Biotechnology shares rose about 64% premarket after announcing a prostate cancer drug partnership with Astellas Pharma, bringing $335 million upfront and up to $1.37 billion in milestones. Updated Phase 1 data for VIR-5500 showed 82% of PSA-evaluable patients had at least a 50% PSA drop. Vir expects its cash to fund operations into Q2 2028. Fourth-quarter 2025 revenue reached $64.1 million, up from $12.4 million.

ImmunityBio shares traded near a 52-week high premarket after the European Commission granted conditional approval for ANKTIVA with BCG in bladder cancer. The company named Accord Healthcare and a Dublin unit for its European launch. Shares closed at $8.61 Thursday, up 41.9% Wednesday on heavy volume. Investors await updates at ASCO GU and feedback from the U.S. FDA.

ImmunityBio shares slipped 0.5% to $8.50 premarket Thursday after surging 41.9% on news the European Commission granted conditional marketing authorization for its bladder cancer therapy Anktiva plus BCG. The approval allows commercial rollout across 30 European countries for adults with BCG-unresponsive non-muscle invasive bladder cancer. Trading volume spiked to 78 million shares after the announcement.

Ocular Therapeutix shares rose 30% in premarket trading Tuesday ahead of topline Phase 3 results for its wet AMD drug, AXPAXLI. The company will discuss the data in an 8 a.m. ET webcast, with full results set for release at the Macula Society meeting Feb. 25-28.

ImmunityBio shares climbed 7% to $6.37 in premarket trading Tuesday, rebounding from a 10% drop before the Presidents Day market closure. Volume was light at 79,000 shares. Investors are watching for updates on Anktiva at the ASCO Genitourinary Cancers Symposium starting Feb. 26 and the company’s next earnings report expected in early March.

Vertex Pharmaceuticals shares rose 5.7% to $491.47 after hours Friday following a 2026 revenue forecast of up to $13.1 billion, matching Wall Street’s expectations. Fourth-quarter revenue reached $3.19 billion, with cystic fibrosis drugs Trikafta and Kaftrio accounting for $2.57 billion. Journavx prescriptions topped 550,000 through 2025. Casgevy sales more than tripled from the previous quarter.

Erasca shares rose 1.1% to $12.44 Friday morning after updates on ERAS-0015 and ERAS-4001 at Guggenheim’s biotech summit. The company reported $341.8 million in cash at 2025 year-end and expects funding to last into the first half of 2029. Next investor focus: Feb. 26 fireside chat at Oppenheimer’s healthcare conference.